CN110540945B - 一种詹氏乳杆菌及其用于制备阴道抑菌药物的应用 - Google Patents
一种詹氏乳杆菌及其用于制备阴道抑菌药物的应用 Download PDFInfo
- Publication number
- CN110540945B CN110540945B CN201810567945.XA CN201810567945A CN110540945B CN 110540945 B CN110540945 B CN 110540945B CN 201810567945 A CN201810567945 A CN 201810567945A CN 110540945 B CN110540945 B CN 110540945B
- Authority
- CN
- China
- Prior art keywords
- vaginal
- lactobacillus
- lactobacillus jensenii
- strain
- jensenii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241001561398 Lactobacillus jensenii Species 0.000 title claims abstract description 93
- 229940124350 antibacterial drug Drugs 0.000 title description 5
- 230000001580 bacterial effect Effects 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 15
- 244000052616 bacterial pathogen Species 0.000 claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- 229940079593 drug Drugs 0.000 claims abstract description 9
- 210000002919 epithelial cell Anatomy 0.000 claims abstract description 9
- 208000013464 vaginal disease Diseases 0.000 claims abstract description 8
- 238000004321 preservation Methods 0.000 claims abstract description 7
- 238000011282 treatment Methods 0.000 claims abstract description 5
- 241000186660 Lactobacillus Species 0.000 claims description 27
- 229940039696 lactobacillus Drugs 0.000 claims description 24
- 206010046914 Vaginal infection Diseases 0.000 claims description 10
- 241000207201 Gardnerella vaginalis Species 0.000 claims description 8
- 241000588724 Escherichia coli Species 0.000 claims description 5
- 241000191967 Staphylococcus aureus Species 0.000 claims description 5
- 241000222122 Candida albicans Species 0.000 claims description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 4
- 241000607142 Salmonella Species 0.000 claims description 4
- 229940095731 candida albicans Drugs 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 claims description 2
- 208000007074 Trichomonas Vaginitis Diseases 0.000 claims description 2
- 208000025206 Trichomonas vaginitis urogenital infection Diseases 0.000 claims description 2
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 claims description 2
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 abstract description 22
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 22
- 210000001215 vagina Anatomy 0.000 abstract description 18
- 235000014655 lactic acid Nutrition 0.000 abstract description 11
- 239000004310 lactic acid Substances 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 7
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 6
- 230000021164 cell adhesion Effects 0.000 abstract description 4
- 238000009629 microbiological culture Methods 0.000 abstract description 4
- 239000002068 microbial inoculum Substances 0.000 abstract description 3
- 231100000252 nontoxic Toxicity 0.000 abstract description 3
- 230000003000 nontoxic effect Effects 0.000 abstract description 3
- 230000002503 metabolic effect Effects 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 description 24
- 238000012360 testing method Methods 0.000 description 21
- 239000001963 growth medium Substances 0.000 description 19
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 15
- 210000003756 cervix mucus Anatomy 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 229920001817 Agar Polymers 0.000 description 12
- 239000008272 agar Substances 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 8
- 230000003749 cleanliness Effects 0.000 description 7
- 239000002207 metabolite Substances 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 230000001954 sterilising effect Effects 0.000 description 7
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 6
- 238000012408 PCR amplification Methods 0.000 description 6
- 208000037009 Vaginitis bacterial Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 231100000820 toxicity test Toxicity 0.000 description 5
- 229930182566 Gentamicin Natural products 0.000 description 4
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 108010059993 Vancomycin Proteins 0.000 description 4
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 4
- 230000003385 bacteriostatic effect Effects 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 229960003276 erythromycin Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 229960002518 gentamicin Drugs 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 229960003165 vancomycin Drugs 0.000 description 4
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 4
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 4
- 241000207202 Gardnerella Species 0.000 description 3
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 3
- 241000282567 Macaca fascicularis Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108010001478 Bacitracin Proteins 0.000 description 2
- 238000003794 Gram staining Methods 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-Lactic acid Natural products C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 201000008100 Vaginitis Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229960003022 amoxicillin Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 229960004099 azithromycin Drugs 0.000 description 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 2
- 229960003071 bacitracin Drugs 0.000 description 2
- 229930184125 bacitracin Natural products 0.000 description 2
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229960004755 ceftriaxone Drugs 0.000 description 2
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000009642 citrate test Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 229960003306 fleroxacin Drugs 0.000 description 2
- XBJBPGROQZJDOJ-UHFFFAOYSA-N fleroxacin Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(CCF)C2=C1F XBJBPGROQZJDOJ-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960002260 meropenem Drugs 0.000 description 2
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 229960001019 oxacillin Drugs 0.000 description 2
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229960002292 piperacillin Drugs 0.000 description 2
- IVBHGBMCVLDMKU-GXNBUGAJSA-N piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- DWHGNUUWCJZQHO-ZVDZYBSKSA-M potassium;(2s,5r,6r)-6-[[(2r)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2r,3z,5r)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 DWHGNUUWCJZQHO-ZVDZYBSKSA-M 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 239000001974 tryptic soy broth Substances 0.000 description 2
- 108010050327 trypticase-soy broth Proteins 0.000 description 2
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229930182843 D-Lactic acid Natural products 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000015580 Increased body weight Diseases 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 241000218492 Lactobacillus crispatus Species 0.000 description 1
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000186783 Lactobacillus vaginalis Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000013494 PH determination Methods 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001775 anti-pathogenic effect Effects 0.000 description 1
- 238000002829 antibacterial sensitivity test Methods 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229940022769 d- lactic acid Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 229940093496 esculin Drugs 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- CEQFOVLGLXCDCX-WUKNDPDISA-N methyl red Chemical compound C1=CC(N(C)C)=CC=C1\N=N\C1=CC=CC=C1C(O)=O CEQFOVLGLXCDCX-WUKNDPDISA-N 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- PRWXGRGLHYDWPS-UHFFFAOYSA-L sodium malonate Chemical compound [Na+].[Na+].[O-]C(=O)CC([O-])=O PRWXGRGLHYDWPS-UHFFFAOYSA-L 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
条件 | 总菌数/克干粉 | 活菌率/% |
0个月 | <![CDATA[4.5*10<sup>10</sup>]]> | / |
3个月,2-8℃ | <![CDATA[3.2*10<sup>10</sup>]]> | 71.1% |
3个月,25℃ | <![CDATA[2.6*10<sup>10</sup>]]> | 57.8% |
6个月,2-8℃ | <![CDATA[2.5*10<sup>10</sup>]]> | 55.6% |
6个月,25℃ | <![CDATA[1.3*10<sup>9</sup>]]> | 28.9% |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810567945.XA CN110540945B (zh) | 2018-05-29 | 2018-05-29 | 一种詹氏乳杆菌及其用于制备阴道抑菌药物的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810567945.XA CN110540945B (zh) | 2018-05-29 | 2018-05-29 | 一种詹氏乳杆菌及其用于制备阴道抑菌药物的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110540945A CN110540945A (zh) | 2019-12-06 |
CN110540945B true CN110540945B (zh) | 2023-04-25 |
Family
ID=68701264
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810567945.XA Active CN110540945B (zh) | 2018-05-29 | 2018-05-29 | 一种詹氏乳杆菌及其用于制备阴道抑菌药物的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110540945B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111471623A (zh) * | 2020-04-21 | 2020-07-31 | 广东龙创基药业有限公司 | 三种乳杆菌的组合物及其用途 |
CN113862188B (zh) * | 2021-10-15 | 2023-06-16 | 广东一元兰欣生物科技有限公司 | 一株格氏乳杆菌ls03及其应用 |
CN114350561B (zh) * | 2022-01-05 | 2023-06-13 | 江南大学 | 一株缓解阴道加德纳菌引起的炎症的詹氏乳杆菌及其应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE207755T1 (de) * | 1998-04-30 | 2001-11-15 | Vesely Renata Maria Cavaliere | Pharmazeutische zusammensetzungen enthaltend lactobacillus brevis und lactobacillus salivarius zur behandlung von vaginainfektionen |
CN102851248B (zh) * | 2012-09-18 | 2013-10-23 | 中国科学院微生物研究所 | 用于防治细菌性阴道病的詹氏乳杆菌 |
CN104293718B (zh) * | 2014-10-11 | 2017-01-18 | 中国科学院微生物研究所 | 一株詹氏乳杆菌及其应用 |
WO2017163216A1 (en) * | 2016-03-24 | 2017-09-28 | Probiotical S.P.A. | Lactic acid bacterial composition for the treatment of bacterial vaginal infections by gardnerella vaginalis and, if present, of concurrent fungal infections |
CN107299065B (zh) * | 2017-06-20 | 2020-02-14 | 广东强基药业有限公司 | 一种植物乳杆菌及其用于制备阴道抑菌药物的应用 |
CN108004187B (zh) * | 2018-01-11 | 2020-03-10 | 广东龙创基药业有限公司 | 一种格氏乳杆菌及其用于制备阴道抑菌药物的应用 |
-
2018
- 2018-05-29 CN CN201810567945.XA patent/CN110540945B/zh active Active
Non-Patent Citations (1)
Title |
---|
钟燕等.鼠李糖乳杆菌GR-1和罗伊氏乳杆菌RC-14防治阴道炎的研究进展.《国际妇产科学杂志》.2013,第40卷(第5期),第428-431页. * |
Also Published As
Publication number | Publication date |
---|---|
CN110540945A (zh) | 2019-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108004187B (zh) | 一种格氏乳杆菌及其用于制备阴道抑菌药物的应用 | |
CN107299065B (zh) | 一种植物乳杆菌及其用于制备阴道抑菌药物的应用 | |
US9937214B2 (en) | Lactobacillus crispatus and application thereof | |
CN108004188B (zh) | 一种鼠李糖乳杆菌及其用于制备阴道抑菌药物的应用 | |
CN107267415B (zh) | 一种罗伊氏乳杆菌及其用于制备阴道抑菌药物的应用 | |
WO2021027740A1 (zh) | 多联乳杆菌组合物及其在女性阴道健康中的应用 | |
CN111088178B (zh) | 一种产乳酸和h2o2的乳杆菌及其应用 | |
CN110777087B (zh) | 一种约氏乳杆菌及其应用 | |
TWI627276B (zh) | 新穎之卷曲乳酸桿菌(lactobacillus crispatus)菌株 | |
WO2021027742A1 (zh) | 一种卷曲乳杆菌及其应用 | |
CN111100821B (zh) | 一种链球菌及其应用 | |
CN110540945B (zh) | 一种詹氏乳杆菌及其用于制备阴道抑菌药物的应用 | |
CN111471623A (zh) | 三种乳杆菌的组合物及其用途 | |
CN114591875B (zh) | 一种改善阴道环境的嗜酸乳杆菌la88及其培养方法与应用 | |
CN116218708A (zh) | 乳杆菌、多联乳杆菌复合物、制剂及其应用 | |
CN112063566B (zh) | 一株屎肠球菌及其应用 | |
CN110538201A (zh) | 一种乳杆菌组合物及其用途 | |
CN117511826B (zh) | 尿路粘液乳杆菌及其应用 | |
CN117535206B (zh) | 一种尿路粘液乳杆菌及其应用 | |
CN117535208A (zh) | 一种卷曲乳杆菌及其在女性生殖道健康中的应用 | |
CN117683691A (zh) | 一株罗伊氏粘液乳杆菌及其在制备用于防治阴道炎药物中的应用 | |
CN117363511A (zh) | 一种可改善阴道炎疾病的融合魏斯氏菌及其应用 | |
CN117535207A (zh) | 一种格氏乳杆菌及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240312 Address after: 521000 Factory Building on Plot JN02-15-1, Shenchao Road, Jingnan Branch, Zhongshan (Chaozhou) Industrial Transfer Industrial Park, Fengquanhu High tech Zone, Chaozhou City, Guangdong Province Patentee after: GUANGDONG LONGCHUANGJI PHARMACEUTICAL CO.,LTD. Country or region after: China Address before: 515644 beside Longtou stork Road, Longhu Town, Chao'an District, Chaozhou City, Guangdong Province Patentee before: GUANGDONG QIANGJI PHARMACEUTICAL Co.,Ltd. Country or region before: China Patentee before: GUANGDONG LONGCHUANGJI PHARMACEUTICAL CO.,LTD. Patentee before: Zhao Xiangjiang |
|
TR01 | Transfer of patent right |